Equities

IFR US ECM Pricings

 |  Robert Sherwood

Aevex (US, aerospace and defense) ─ $320m IPO. 16m shares (Primary, Secondary) at $20.00 versus $18-$21 marketing. GS, BOFA, JEFF. NYSE "AVEX". Madison Dearborn is the controlling shareholder. 5% DSP.

Alamar Biosciences (US, medtech) ─ $191.3m IPO. 11.3m shares (Primary) at $17.00 versus $15-$17 marketing. JPM, BOFA, TDC, LEER, STFL. Upsized from 9.4m shares. Nasdaq “ALMR”.

Jatt II Acquisition (Cayman Islands) ─ $60m IPO. 6m shares (Primary) at $10.00. GUGG. Nasdaq “JATT”. Stock-only structure. Someit Sidhu. Life sciences. 24 months. 100% in trust. Access Industries indicated for $30m of the offering.

Kailera Therapeutics (US, biotech) ─ $625m IPO. 39.1m shares (Primary) at $16.00 versus $14-$16 marketing. JPM, JEFF, LEER, TDC, EVER. Nasdaq “KLRA”. Upsized from 33.3m shares. Affiliates of Bain Capital indicated for up to $225m of the offering.

Trevi Therapeutics (US, biotech) ─ $150.8m ABB. 11.6m shares (Primary) at $13.00 versus $13.00-$13.50 marketing and $14.27 last sale. MS, LEER, CANT, STFL. Wall cross.

Topics
Equity Capital Initial Public Offerings (IPO) Americas Structured Equity US Dollar North America Canada Marketed Follow-Ons ABBs and Block Trades United States
Issuers
Aevex Holdings LLC Alamar Biosciences Inc Kailera Therapeutics Inc Trevi Therapeutics Inc (TRVI.O) Jatt II Acquisition Corp